तुलना करने के लिए मीट्रिक्स | 310210 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध310210पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −26.7x | −15.2x | −0.2x | |
PEG अनुपात | 0.44 | −0.08 | 0.00 | |
क़ीमत/बुक | 26.7x | 2.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 443.5x | 24.0x | 2.7x | |
अपसाइड (विश्लेषक लक्ष्य) | 234.0% | 105.1% | 68.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.0% | 11.5% | अनलॉक करें |
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.